Dear D2R Community,
I am deeply honored to step into the role of Chief Scientific Officer for the DNA to RNA (D2R) Initiative, and I want to take this opportunity to share my vision for the future as we embark on this exciting journey together.
The rapid development of RNA technologies, illustrated by the successful creation of mRNA-based vaccines for Covid-19, highlights what can be achieved when scientists around the world join forces, and industry and governments invest to accelerate scientific progress. We have all witnessed RNA as a transformative therapeutic tool, capable of tackling some of the most challenging health issues facing our society today, including not only infections but also rare diseases, cancer, and chronic diseases.
As we move forward, our mission is clear: to develop next-generation RNA therapies that are accessible, equitable, and inclusive. The D2R Initiative will stand out for its interdisciplinary approach, fostering collaboration among researchers, clinicians, and industry partners to translate our research into tangible health benefits for diverse populations. Engaging with industry partners will be crucial, as their expertise and resources will help us commercialize our innovations and ensure they reach those who need them most.
D2R鈥檚 research is built around six foundational axes to be able to deliver effective, accessible, and culturally relevant RNA therapies. This includes conducting population studies to identify health determinants, enhancing RNA therapeutics for new drug development, creating targeted delivery systems using bioprocessing and nanotechnology, exploring personalized medicine through clinical research, supporting biomarker discovery with data science, and addressing ethical and socioeconomic factors.
We are not only committed to tackling major health challenges such as cancer, infectious diseases, and rare diseases but also to ensuring that our breakthroughs reach all communities, especially underserved and equity deserving groups. By prioritizing equitable practices and championing Indigenous-led research, we will work to ensure that our research and development are culturally safe and relevant.
As we embark on this journey, I encourage each of you to think about how we can leverage our collective expertise. Let us challenge the status quo and embrace a culture of collaboration that values diverse perspectives. Together, we have the potential to deliver groundbreaking RNA therapies that can change lives and shape the future of healthcare.
Thank you for your continued dedication and support.
Warm regards,
Philippe Gros
Chief Scientific Officer, DNA to RNA (D2R) Initiative
